Immunoinflammatory Regulation of Esketamine in Septic Patients

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 28, 2021

Primary Completion Date

October 30, 2026

Study Completion Date

October 30, 2026

Conditions
EsketamineSepsisInflammatory ResponseImmunosuppression
Interventions
DRUG

Esketamine hydrochloride

After inclusion, septic patients will be received a single intravenous injection of esketamine (0.7 mg/kg), and then followed by an intravenous administration of esketamine (0.07 mg/kg/h) with an infusion pump for three consecutive days.

Trial Locations (2)

430022

NOT_YET_RECRUITING

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

RECRUITING

Department of Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER